Home / Expertise / Life Sciences & Healthcare

Life Sciences & Healthcare

Switzerland

Our Life Sciences & Healthcare team consists of specialised attorneys who will advise and represent you in all legal matters competently and tailored to the special needs of your company. 

With more than 300 lawyers specialising in the Life Sciences & Healthcare sector worldwide and the support of the Life Sciences Asia Pacific Network (LAN), we at CMS are very familiar with the economic, commercial and legal needs of our clients in those industries.

Reputation

We have been working successfully for many years with leading companies in the Life Sciences sector in the fields of pharmaceuticals, medical devices, biotechnology, chemistry, foodstuffs and cosmetics. These include the world’s most important pharmaceutical companies and the world’s leading medical device companies. In the Healthcare sector, we advise and represent all relevant medical service providers (hospitals, HMOs, nursing homes, laboratories, physicians, pharmacists, etc.) and their associations.

Comprehensive advice and representation

We regularly advise our Life Sciences clients on their day-to-day business, for example in:

  • Research and development (particularly in clinical trials)
  • Patent enforcement
  • Regulatory authorisations
  • Advertising and distribution issues
  • Pricing strategies and reimbursements under social security law
  • Compliance
  • Data protection

We support our Healthcare clients in particular in the areas of:

  • Social security regulatory authorisations
  • Professional law
  • Data protection
  • Tariff negotiations and tariff settings
  • Planning (hospital planning, planning of highly-specialised medicine)
  • Liability issues and compliance

Whether you require professional support in the area of contracts, strategic agreements or in competition and antitrust law, or an expert opinion, are planning a corporate transaction or seek to engage in legal proceedings or are affected by legal, administrative or criminal proceedings, we would be delighted to assist you.

Industry knowledge

Many of our experts have worked in Life Sciences & Healthcare companies prior to joining CMS, gaining extensive knowledge in pharmaceuticals, medical devices, biotechnology, chemistry, foodstuffs, cosmetics and medical services. Through our active membership in the most important industry associations and our participation in the legislative process, we contribute to shaping the legal and regulatory framework for the Life Sciences & Healthcare sector.


Find out more in our Life Sciences & Healthcare brochure

Read more Read less

'Due to very good networking', CMS 'can provide know-how in a variety of matters', especially at a multi-jurisdictional level. Regulatory, compliance, financial benefits and pricing advice, as well as the negotiation of agreements and representation in court form the main areas of expertise.

The Legal 500, Healthcare and life sciences, Switzerland, 2019
17/04/2018
Life Sci­ences & Health­care Prac­tice Group Switzer­land

Feed

Show only
24 Apr 20
CMS again achieves top po­s­i­tions in BIL­ANZ / Le Temps...
Ranked as one of the best law firms in Switzer­land
26 May 20
European Com­mis­sion must ad­dress in­tel­lec­tu­al prop­erty and AI
The Com­mit­tee on Leg­al Af­fairs (JURI) of the European Par­lia­ment has pub­lished three draft re­ports re­lat­ing to ar­ti­fi­cial in­tel­li­gence (AI). This note is about the draft re­port on in­tel­lec­tu­al prop­erty...
CMS Ex­pert Guide to Ad­vert­ising of Medi­cines and Med­ic­al...
22 May 20
For­eign in­vest­ments in Ger­man life sci­ence com­pan­ies be­come sub­ject...
In re­sponse to the COV­ID-19 pan­dem­ic, Ger­many has widened the scope of its in­vest­ment con­trol to in­clude nu­mer­ous life sci­ence com­pan­ies. The amend­ments to the For­eign Trade and Pay­ments Or­din­ance ("AWV")...
CMS Ex­pert Guide to a Leg­al Roadmap to Can­nabis
20 May 20
Use of product pic­tures in ad­vert­ise­ment un­der re­vised Swiss copy­right...
On 1 April 2020, the Swiss Copy­right Act ("CopA") was re­vised to ad­apt Swiss copy­right law to the new di­git­al age. One of the of­ten-high­lighted changes is the ab­ol­ish­ment of the high threshold for the...
08 Jul 19
CMS ad­vises Bruker on the ac­quis­i­tion of PMOD Tech­no­lo­gies...
04 May 20
EPO Board of ap­peal re­mits to ex­amin­ing di­vi­sion when pri­or art search...
In Mod­el de­term­in­a­tion sys­tem/Ac­cen­ture Glob­al Ser­vices Lim­ited (Case T-1159/15), the board of ap­peal finds that need to per­form a pri­or art search con­sti­tutes a spe­cial reas­on to re­mit the ap­peal ap­plic­a­tion...
26/04/2019
CMS once again one of the lead­ing law firms in Switzer­land
BIL­ANZ Rank­ing 2019
30 Apr 20
USPTO finds an in­ven­tion cre­ated by an AI ma­chine is not pat­entable
The US Pat­ent and Trade Mark Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The USPTO ac­cep­ted the in­dic­a­tion...
16 Apr 19
CMS Switzer­land fur­ther im­proves its rank­ing with The...
17 Apr 20
Is a pri­vacy-friendly use of mo­bile ap­plic­a­tions to com­bat COV­ID-19...
A Pan-European Ap­proach to the Use of Mo­bile Apps and Mo­bile Data With its Re­com­mend­a­tion of 8 April 2020 on steps and meas­ures to de­vel­op a com­mon ap­proach to the use of mo­bile ap­plic­a­tions and mo­bile...